Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.   

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line. 

Key clinical takeaways: 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0 

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/giconnect 

X: https://x.com/giconnectInfo 

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA. 

This podcast is developed by cor2ed.com 

Published May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.   

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.   

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey. 

What does the patient pathway look like from both perspectives?  What are the needs of Medical Oncologists and patients when navigating the treatment journey?  What do patients need from their oncologists?  What do oncologists think their patients need from them?  Are these needs matched by the support currently available?   

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0 

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t 

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. 

This podcast is developed by cor2ed.com 

Published on May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC 

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. 

The conversation unfolds to cover; 

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published on May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives 

This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos. 

In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting. 

Listen to different expert perspectives on 

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1 

Or watch on YouTube: https://youtu.be/3vMCzR1jqbI 

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published on April 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. 

Key topics include 

Clinical takeaways 

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only. 

This video was developed by https://cor2ed.com/ 

Published March 2025 

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.  

Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.  

Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.  

Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes. 

Key clinical takeaways: 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/ntrk-connect/  

X: https://x.com/PresOnc_Connect  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific. 

This podcast is developed by cor2ed.com 

Published March 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Key clinical takeaways:  

The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC. 

Key topics include: 

Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/ 

Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true  

X: https://x.com/OBGynConnect  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast. 

This podcast is developed by cor2ed.com 

Published February 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Intermediate HCC – The evolving role of IO 

In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.  

Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC. 

Key clinical takeaways:  

You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/ 

Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect/

X https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. 

This podcast is developed by cor2ed.com 

Published on January 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice. 

Key topics include: 

Key clinical takeaways:  

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/  

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published January 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies. 

Topics include: 

Key clinical takeaways:  

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/  

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published December 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.